ERBB2 and breast cancer: However, the anti-HER2 agents, including trastuzumab, lapatinib, ado-trastuzumab emtansine (T-DM1) etc., are milestone in the treatment of BC, which dramatically improved the survival rates and prognosis in HER2-positive BC, and a phenomenal success treatment is still going on6–8.